AMLX — Amylyx Pharmaceuticals, Inc. stock price, charts and financials
QT72Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
32.41
-1.53-4.51%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -2.45 | Insider Own | 37.43% | Shs Outstand | 111.19M | Perf Week | 2.50% |
| Market Cap | 3.60B | Forward P/E | - | EPS next Y | -1.18 | Insider Trans | -0.28% | Shs Float | 82.38M | Perf Month | -16.04% |
| Enterprise Value | 3.36B | PEG | - | EPS next Q | -0.38 | Inst Own | - | Short Float | 15.46% | Perf Quarter | 106.83% |
| Income | -166.00M | P/S | 12.05 | EPS this Y | 38.49% | Inst Trans | - | Short Ratio | 5.14 | Perf Half Y | 130.68% |
| Sales | 299.00M | P/B | 15.08 | EPS next Y | 21.46% | ROA | -57.49% | Short Interest | 12.74M | Perf YTD | 168.29% |
| Book/sh | 2.15 | P/C | 14.36 | EPS next 5Y | - | ROE | -52.92% | 52W High | 41.14 -21.22% | Perf Year | 153.80% |
| Cash/sh | 2.26 | P/FCF | - | EPS past 3/5Y | - | ROIC | -66.32% | 52W Low | 10.83 199.26% | Perf 3Y | 61.00% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.22% 5.25% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 11.23 | EPS Y/Y TTM | 44.70% | Oper. Margin | 0.00% | ATR (14) | 1.90 | Perf 10Y | - |
| Dividend Ex-Date | Mar 28, 2018 | Quick Ratio | 12.12 | Sales Y/Y TTM | 243.68% | Profit Margin | 0.00% | RSI (14) | 53.11 | Recom | 2.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.12 | EPS Q/Q | 15.22% | SMA20 | -5.94% | Beta | 0.80 | Target Price | 52.20 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | - | SMA50 | 20.57% | Rel Volume | 0.83 | Prev Close | 33.94 |
| Employees | 136 | LT Debt/Eq | 0.02 | Earnings | Nov 05 | SMA200 | 83.16% | Avg Volume | 2.48M | Price | 32.41 |
| IPO Date | Jan 07, 2022 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -8.06% - | Net Debt/EBITDA | 0.29 | Volume | 2,048,581 | Change | -4.51% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-27-26 | Reiterated | Guggenheim | Buy | $55 → $57 |
| Aug-19-26 | Reiterated | Guggenheim | Buy | $40 → $55 |
| Aug-18-26 | Reiterated | Robert W. Baird | $28 → $52 | |
| Aug-18-26 | Reiterated | UBS | $34 → $55 | |
| Aug-18-26 | Reiterated | HC Wainwright & Co. | Buy | $34 → $55 |
| Aug-17-26 | Reiterated | Mizuho | Outperform | $24 → $30 |
| Aug-07-26 | Reiterated | Robert W. Baird | $19 → $28 | |
| Jul-20-26 | Reiterated | Mizuho | Outperform | $21 → $24 |
| Jun-25-26 | Reiterated | Guggenheim | Buy | $25 → $40 |
| Jun-08-26 | Reiterated | H.C. Wainwright | Buy | $28 → $34 |
Latest News· Times ET
Sep-15-26
Sep-15-2610:11PM
Sep-10-26
Sep-10-2612:08PM
09:33AM
03:44AM
Sep-08-26
Sep-08-2609:00AM
Sep-01-26
Aug-29-26
Aug-29-2612:57AM
Aug-27-26
Aug-26-26
Aug-26-2611:35PM
Aug-23-26
Aug-23-2611:47PM
Aug-22-26
Aug-21-26
Aug-19-26
Aug-19-2608:00PM
Company
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 299 | 0 | 87 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 138 | 1 | 42 | — | — | — | — | — | |
| Gross Profit | 159 | -1 | 45 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 181 | 63 | 114 | — | — | — | — | — | |
| Research and Development | 135 | 90 | 104 | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 142 | — | — | — | — | — | |
| Operating Income | -154 | -153 | -315 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -6 | 9 | 13 | — | — | — | — | — | |
| Net Income Before Taxes | -164 | -145 | -302 | — | — | — | — | — | |
| Income Taxes | 4 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -166 | -145 | -302 | — | — | — | — | — | |
| Net Income From Continuing Operations | -166 | -145 | -302 | — | — | — | — | — | |
| Net Income | -166 | -145 | -302 | — | — | — | — | — | |
| EPS (Recurring) | -2.44 | -1.53 | -4.43 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.44 | -1.53 | -4.43 | — | — | — | — | — | |
| EPS (Diluted) | -2.45 | -1.53 | -4.43 | — | — | — | — | — | |
| EBITDA | -160 | -144 | -291 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.37 | — | 2.95 | — | — | — | — | — | |
| Gross Margin | 53.18 | — | 51.72 | — | — | — | — | — | |
| Operating Margin | -51.51 | — | -362.07 | — | — | — | — | — | |
| Net Margin | -55.52 | — | -347.13 | — | — | — | — | — | |
| Shares Outstanding | 68 | 95 | 68 | — | — | — | — | — | |
| Market Capitalization | 2,204 | 1,148 | 257 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| FRATES JAMES M | Chief Financial Officer | Sep 10 '26 | Sale | 32.36 | 10,810 | 349,821 | 233,625 | Sep 14 |
| Bedrosian Camille L | Chief Medical Officer | Sep 10 '26 | Sale | 32.40 | 10,028 | 324,868 | 278,064 | Sep 14 |
| Mazzariello Gina | Chief Legal Officer | Sep 10 '26 | Sale | 32.46 | 9,536 | 309,507 | 190,838 | Sep 14 |
| Klee Justin B. | Co-Chief Executive Officer | Sep 10 '26 | Sale | 32.18 | 30,464 | 980,263 | 3,613,056 | Sep 14 |
| Cohen Joshua B | Co-Chief Executive Officer | Sep 10 '26 | Sale | 32.19 | 30,464 | 980,504 | 3,613,123 | Sep 14 |
| Firestone Karen | Director | Aug 31 '26 | Option Exercise | 3.40 | 50,000 | 170,250 | 116,900 | Sep 02 |
| Mazzariello Gina | Chief Legal Officer | Jul 10 '26 | Sale | 17.61 | 15,000 | 264,122 | 179,090 | Jul 13 |
| Mazzariello Gina | Chief Legal Officer | Jul 09 '26 | Sale | 18.32 | 15,000 | 274,746 | 194,090 | Jul 13 |
| Firestone Karen | Director | May 21 '26 | Buy | 13.51 | 3,800 | 51,338 | 66,900 | May 26 |
| Cohen Joshua B | Co-Chief Executive Officer | Mar 02 '26 | Sale | 14.48 | 29,282 | 424,120 | 3,334,683 | Mar 04 |
| Klee Justin B. | Co-Chief Executive Officer | Mar 02 '26 | Sale | 14.47 | 29,282 | 423,760 | 3,334,616 | Mar 04 |
| Bedrosian Camille L | Chief Medical Officer | Mar 02 '26 | Sale | 14.58 | 6,461 | 94,205 | 169,295 | Mar 04 |
| FRATES JAMES M | Chief Financial Officer | Mar 02 '26 | Sale | 14.52 | 7,909 | 114,851 | 165,638 | Mar 04 |
| Mazzariello Gina | Chief Legal Officer | Mar 02 '26 | Sale | 14.52 | 6,844 | 99,378 | 134,430 | Mar 04 |
| Mazzariello Gina | Chief Legal Officer | Feb 23 '26 | Sale | 14.14 | 3,419 | 48,352 | 141,274 | Feb 25 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.